Premium
Poikilodermatous mycosis fungoides with CD30‐positive large cell transformation successfully treated by brentuximab vedotin
Author(s) -
Popadic Svetlana,
Lekic Branislav,
Tanasilovic Srdjan,
Bosic Martina,
Nikolic Milos
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13152
Subject(s) - brentuximab vedotin , mycosis fungoides , medicine , cd30 , dermatology , cytotoxic t cell , oncology , lymphoma , biology , biochemistry , in vitro
We present a patient with a 33‐year history of poikilodermatous mycosis fungoides (MF) who subsequently developed CD30‐positive large cell transformation. After 6 years of conventional MF treatment, side effects of therapy and/or concomitant diseases prevented the previously applied treatment modalities. The CD30‐directed antibody‐cytotoxic drug conjugate (brentuximab vedotin) was introduced and followed by quick and excellent therapeutic response.